Anti-interleukin 13 for asthma: stick or twist?

Slides:

Advertisements

Similar presentations

Individualized Medicine from Prewomb to Tomb Eric J. Topol Cell Volume 157, Issue 1, Pages (March 2014) DOI: /j.cell Copyright.

Advertisements

The Circadian Timekeeping System of Drosophila Paul E. Hardin Current Biology Volume 15, Issue 17, Pages R714-R722 (September 2005) DOI: /j.cub

Healthy clocks, healthy body, healthy mind Akhilesh B. Reddy, John S. O’Neill Trends in Cell Biology Volume 20, Issue 1, Pages (January 2010) DOI:

Signal Jamming Mediates Sexual Conflict in a Duetting Bird Joseph A. Tobias, Nathalie Seddon Current Biology Volume 19, Issue 7, Pages (April 2009)

Regulation of T cell trafficking by the T cell immunoglobulin and mucin domain 1 glycoprotein Stefano Angiari, Gabriela Constantin Trends in Molecular.

The Origins and Evolution of Vertebrate Metamorphosis Vincent Laudet Current Biology Volume 21, Issue 18, Pages R726-R737 (September 2011) DOI: /j.cub

Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)

Lactate dehydrogenase as prognostic factor in limited and extensive disease stage small cell lung cancer – A retrospective single institution analysis.

Biologics in Asthma—The Next Step Toward Personalized Treatment

Volume 102, Issue 1, Pages (January 2008)

Volume 103, Issue 6, Pages (June 2009)

Volume 100, Issue 11, Pages (November 2006)

Thank God for Richard Dawkins?

A stepwise therapeutic approach in severe uncontrolled asthmatic subjects. A stepwise therapeutic approach in severe uncontrolled asthmatic subjects. GINA:

OX40/OX40 Ligand Interactions in T-Cell Regulation and Asthma

Simple versus complex COPD: implications for health-care management

Diagnosis, Evaluation, and Therapy for Severe Refractory Eosinophilic Asthma.

Endotype-driven care pathways in patients with chronic rhinosinusitis

COPD and asthma: the emergency is clear, now is the time for action

Volume 43, Issue 6, Pages (December 2015)

COPD and asthma: the emergency is clear, now is the time for action

Severe Asthma in Primary Care: Identification and Management

Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders Robert P. Hirten, Marietta Iacucci, Shailja Shah,

Blood eosinophils as a marker of eosinophilic exacerbations in COPD

Current application of exhaled nitric oxide in clinical practice

Jennifer L. Ingram, PhD, Monica Kraft, MD

ILCs and T Cells Competing for Space: More Than a Numbers Game

Biologic Therapy and Novel Molecular Targets of Severe Asthma

Lymphoid tissue inducer cells

Nicholas D Walter, Randall Reves, J Lucian Davis

How To Choose a Good Scientific Problem

Effective cross-sector collaborations create sustainability

Two different pathways lead to eosinophilic airway inflammation in asthma. Two different pathways lead to eosinophilic airway inflammation in asthma. In.

Advances in Severe Asthma Management

HIV myths should not be resuscitated

The 3 major types of innate and adaptive cell-mediated effector immunity Francesco Annunziato, PhD, Chiara Romagnani, MD, PhD, Sergio Romagnani, MD Journal.

Volume 362, Pages s6-s7 (December 2003)

Adrian Martineau The Lancet Respiratory Medicine

OX40/OX40 Ligand Interactions in T-Cell Regulation and Asthma

K+ Channel Regulation of Multicompartmental Signal Integration

Diagnosis, Evaluation, and Therapy for Severe Refractory Eosinophilic Asthma.

Confessions of a journal junkie

Biologics and biomarkers for asthma, urticaria, and nasal polyposis

Telling it like it isn't: truth and lies in a post-9/11 world

Thank God for Richard Dawkins?

It’s all about the constraints

Innate Lymphoid Cells in Inflammation and Immunity

Natural “Helper” Cells in the Lung: Good or Bad Help?

Thank you to our diverse (but not diverse enough) reviewers

Debate on long-acting β agonists for asthma: they think it's all over

Pinja Ilmarinen, PhD, Leena E

Inhaled triple therapy in chronic obstructive pulmonary disease

A myriad of responses The Lancet Volume 358, (December 2001)

Asthma and Allergic Inflammation

A remarkable report card on progress in COPD

Lung ILC2s link innate and adaptive responses in allergic inflammation

Mark J. Koury, MD, John H. Newman, MD, John J. Murray, MD

Sputum culture conversion in new TB regimens

Rebecca D. Chason, Joan S. Reisch, PhD, Don C. Rockey, MD

Sachin K. Samuchiwal, PhD, Joshua A. Boyce, MD

Learning Tolerance while Fighting Ignorance

Hematopoietic Stem Cell Heterogeneity Takes Center Stage

How To Choose a Good Scientific Problem

Albert Y. Wu, MD, Sanjiv Sur, MD, J. Andrew Grant, MD

Urban trees and asthma: a call for epidemiological research

Tuft Cells: A New Flavor in Innate Epithelial Immunity

Sickle cell disease: a new era

Autism, maths, and sex: the special triangle

Foundations of Asthma.

Presentation transcript:

Anti-interleukin 13 for asthma: stick or twist? Brian Lipworth, Sunny Jabbal, Chris RuiWen Kuo The Lancet Respiratory Medicine Volume 6, Issue 9, Pages e46-e47 (September 2018) DOI: 10.1016/S2213-2600(18)30275-3 Copyright © 2018 Elsevier Ltd Terms and Conditions

Figure 1 Diagram of biologics and biomarkers in relation to the type 2 inflammatory pathway in asthma Biologics (shown in light blue) include anti-IL-4Rα (dupilumab), anti-IL-5Rα (benralizumab), anti-IL-5 (mepolizumab or reslizumab), anti-IL-13 (tralokinumab or lebrikizumab), anti-IgE (omalizumab), and anti-TSLP (tezepelumab). Biomarkers include FENO, IgE, and eosinophils. IL-4=interleukin 4. IgE=immunoglobulin E. IL-4Rα=interleukin 4 receptor α. Th2=T-helper-2. IL-13=interleukin 13. FENO=fractional exhaled nitric oxide. TSLP=thymic stromal lymphopoietin. ILC-2=type 2 innate lymphoid cells. IL-5=interleukin 5. IL-5Rα=interleukin 5 receptor α. The Lancet Respiratory Medicine 2018 6, e46-e47DOI: (10.1016/S2213-2600(18)30275-3) Copyright © 2018 Elsevier Ltd Terms and Conditions

Figure 2 Blockade of IL-4 and IL-13 IL-13 and IL-4 are involved in trafficking eosinophils from blood vessels into the lungs. Blockade of IL-13 alone is insufficient to suppress tissue eosinophils in the presence of unopposed IL-4 signalling. Combined IL-4 and IL-13 blockade therefore results in putative reduction of lung eosinophils in conjunction with raised blood eosinophils. IL-13=interleukin 13. IL-4=interleukin 4. FENO=fractional exhaled nitric oxide. The Lancet Respiratory Medicine 2018 6, e46-e47DOI: (10.1016/S2213-2600(18)30275-3) Copyright © 2018 Elsevier Ltd Terms and Conditions